乌司他丁、 奥曲肽联合应用于急性胰腺炎30例的疗效与A-PACHEⅡ分析

目的:探究乌司他丁、奥曲肽联合应用于急性胰腺炎30例的疗效与APACHEⅡ.方法:研究对象是2014年9月~2016年9月来我院就诊的60例AP患者,按照治疗采用的药物不同划分为例数相同的两组,单一组(n=30)与联合组(n=30),单一组单纯采用奥曲肽治疗,联合组在单一组基础上采用乌司他丁治疗,对比两组治疗效果与APACHEⅡ评分.结果:联合组总治疗有效率93.33%(28/30)显著高于单一组的83.33%(25/30)(λ2=3.864,P=0.026<0.05);治疗后联合组APACHEⅡ评分(5.87±0.34)分显著低于单一组的(7.95±0.34)分(t=3.541,P=0.032<0.05).结论:两种药物联合运用于急性胰腺炎治疗,效果显著,而且有效改善APACHEⅡ评分,值得在急性胰腺炎患者治疗过程中推广应用.     

Inhibitory effects of licochalcone A isolated from Glycyrrhiza inflata root on inflammatory ear edema and tumour promotion in mice

Licochalcone A, 3-a,a-dimethylallyl-4,4'-dihydroxy-6-methoxychalcone, from the root of Glycyrrhiza inflata Beta (Leguminosae) (Xin-jiang liquorice) showed anti-inflammatory action towards mouse ear edema induced by arachidonic acid (AA) and 12-O-tetradecanoylphorbol 13-acetate (TPA) by topical application. Anti-tumour promoting action of licochalcone A was also observed in vivo for mouse skin papilloma initiated by dimethylbenz[a]anthracene (DMBA) and promoted by TPA. It inhibited in vitro 32Pi-incorporation to phospholipids in HeLa cells promoted by TPA. A competitive interaction of licochalcone A with the TPA-receptors in the cell membrane has been suggested.     

A new lignan from the seeds of Sphaerophysa salsula

A new compound, sphaerophysin A (1), together with 16 known compounds (2-17) were obtained from the ethanolic extract of the seeds of Sphaerophysa salsula. The structure of 1 was elucidated on the basis of spectral and chemical evidence. Compounds 2-17 were isolated from the plant for the first time.     

第四批人凝血因子VIII国家标准品制备和标定

目的:建立经两步病毒灭活工艺制备的人凝血因子VIII国家标准品,以替代第三批人凝血因子VIII国家标准品。方法:按《中国药典》2010年版三部对人凝血因子VIII产品的生产工艺要求和质量标准,制备第四批人凝血因子VIII国家标准品(批号20100101),用WHO第七批人凝血因子VIII国际标准品(批号99/678),采用一期法进行协作标定,采用加速破坏试验进行稳定性考察。结果:批号20100101人凝血因子VIII国家标准品效价为12.1IU/支,稳定性好,其它项目指标均达到国家标准品的要求。结论:建立了符合国家标准品要求、并经病毒灭活的第四批人凝血因子VIII国家标准品。     

Inhibitory Effects of Eucommia ulmoides Oliv. Bark on Scopolamine-Induced Learning and Memory Deficits in Mice

Eucommia ulmoides Oliv. Bark (EUE) is commonly used for the treatment of hypertension, rheumatoid arthritis, lumbago, and ischialgia as well as to promote longevity. In this study, we tested the effects of EUE aqueous extract in graded doses to protect and enhance cognition in scopolamine-induced learning and memory impairments in mice. EUE significantly improved the impairment of short-term or working memory induced by scopolamine in the Y-maze and significantly reversed learning and memory deficits in mice as measured by the passive avoidance and Morris water maze tests. One day after the last trial session of the Morris water maze test (probe trial session), EUE dramatically increased the latency time in the target quadrant in a dose-dependent manner. Furthermore, EUE significantly inhibited acetylcholinesterase (AChE) and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus and frontal cortex in a dose-dependent manner. EUE also markedly increased brain-derived neurotrophic factor (BDNF) and phosphorylation of cAMP element binding protein (CREB) in the hippocampus of scopolamine-induced mice. Based on these findings, we suggest that EUE may be useful for the treatment of cognitive deficits, and that the beneficial effects of EUE are mediated, in part, by cholinergic signaling enhancement and/or protection.     

Identification of a major metabolite of danshensu in rat urine and simultaneous determination of danshensu and its metabolite in plasma: application to a pharmacokinetic study in rats

Danshensu, as the effective component of Salvia miltiorrhiza (Danshen), has been widely used in clinical studies for treatment of cardiovascular diseases in China. A new metabolite, 4‐hydroxy‐3‐methoxyphenyllactic acid was isolated from the urine of rats, and its chemical structure was identified by ultraviolet (UV), Infrared Spectroscopy (IR), mass spectrometry (MS) and nuclear magnetic resonance (NMR). Furthermore, a selective and sensitive high performance liquid chromatography‐tandem mass spectrometric (HPLC‐MS/MS) method was developed for the simultaneous quantification of danshensu and its major metabolite, 4‐hydroxy‐3‐methoxyphenyllactic acid, in rat plasma after oral and intravenous administration of danshensu. The separation was performed on a Hypersil Gold C₁₈ column (150 × 2.1 mm i.d., 3.0 µm, Thermo, San jose CA, USA) with gradient elution using a mobile phase composed of methanol and water (containing 0.1% formic acid) at a flow rate of 0.2 mL/min. Linear detection responses were obtained for danshensu and 4‐hydroxy‐3‐methoxyphenyllactic acid ranging from 5 to 10000 ng/mL and 5 to 4000 ng/mL, respectively. The lower limits of quantification (LLOQs) for the two compounds were both 5 ng/mL. The intra‐and inter‐day precision (R.S.D %) were within 5.61% for the two analytes. The average recoveries of the analytes were greater than 72.43%. The method was proved to be stable during all sample storage, preparation and analytic procedures. This method was successfully applied to the pharmacokinetic studies of danshensu and 4‐hydroxy‐3‐methoxyphenyllactic acid after oral and intravenous administration of danshensu in rats.Copyright © 2014 John Wiley & Sons, Ltd.     

低分子肝素的抗血栓作用

研究了低分子肝素 (lowmoleculerweightheparin ,LMWH)的抗血栓作用 .研究表明 ,静脉注射LMWH (40 0、2 0 0IU/kg)能明显降低家兔高、中、低切比粘度 (P <0 .0 1) ,并显著降低家兔体内实验性血栓湿重及干重 (P <0 .0 0 1) ;静脉注射LMWH 40 0、2 0 0IU/kg及 30 0、15 0IU/kg能分别抑制家兔及小鼠ADP诱导的血小板聚集作用 (P <0 .0 0 1) .实验证明 ,相对分子质量为 6 40 0的低分子肝素有抗血栓作用 .     

Inhibitory effect of topiramate on Lewis lung carcinoma metastasis and its relation with AQP1 water channel

AIM: To study the effect of topiramate on tumor metastasis and its relation with aquaporin 1 (AQP1) water channel. METHODS: Lewis lung carcinoma metastatic model was used to determine the effect of topiramate on tumor growth and metastasis. Colorimetric estimation was used to investigate the action of topiramate on carbonic anhydrase (CA) activity. Western blotting and immunohistochemical analysis were used to study the influence of topiramate on AQP1 water channel expression in lungs or tumor tissues of mice bearing Lewis lung carcinoma.     

行不停跳冠状动脉旁路移植术的冠心病患者围术期中医证型变化的研究

目的 探讨行不停跳冠状动脉旁路移植术的冠心病患者围术期中医证型变化的规律.方法 选择北京安贞医院心脏外科2012年1月至2013年5月拟行不停跳冠状动脉旁路移植术386例患者,围术期分为心血瘀阻证组、痰阻心脉证组、气阴两虚证组和心肾阴虚证组,术前,术后3 d、7 d、3个月和6个月分析中医证型并分析变化规律.结果 386例患者术前分型结果心血瘀阻证者占67.9%（262/386）,痰阻心脉证者占13.2%（51/386）,气阴两虚证者占12.2%（47/386）,心肾阴虚证者占6.7%（26/386）,痰阻心脉证患者三支病变比例较高[92.2%（47/51）],与其他3组比较,差异有统计学意义（P=0.011）.术后第3天,心血瘀阻证为5.4%（21/386）,痰阻心脉证为90.7%（350/386）,较术前明显增加,差异有统计学意义（P=0.021）.气阴两虚证为2.1%（8/386）,痰阻心脉证为1.5%（6/386）,另有0.3%（1/386）演变为阳气虚衰证;术后7 d,痰阻心脉为80.8%（312/386）;术后3～6个月痰阻心脉证为20.3%（78/386）和15.3%（56/386）,较术后7 d比较,差异有统计学意义（P=0.011,P=0.006）.结论 拟行不停跳冠状动脉旁路移植术的冠心病患者术前中医证型以心血瘀阻为主;痰阻心脉病变相对重且术后比例大幅增加.临床上应该高度重视这一证型的患者,并根据证型变化应用中西医联合治疗.     

2007 年至 2011 年我院门诊核苷类抗病毒药应用简

目的调查医院门诊核苷类抗病毒药的应用情况,分析其发展趋势,为临床合理用药提供参考。方法对医院门诊核苷类抗病毒药的销售数量、金额、用药频度（DDDs）、日均费用（DDC）等进行统计、分析。结果核苷类抗病毒药的销售数量、金额、DDDs均呈逐年增长趋势。结论医院核苷类抗病毒药应用基本合理,符合用药特点,但用药时应关注不良反应的发生,使用药更加安全、有效、经济、合理。